Compare WB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WB | TRVI |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2014 | 2019 |
| Metric | WB | TRVI |
|---|---|---|
| Price | $7.78 | $17.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $14.00 | ★ $21.55 |
| AVG Volume (30 Days) | 947.0K | ★ 3.0M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.49% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $1.73 | N/A |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.09 | $6.55 |
| 52 Week High | $12.96 | $20.22 |
| Indicator | WB | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 49.62 |
| Support Level | $7.09 | $16.24 |
| Resistance Level | $10.49 | $20.15 |
| Average True Range (ATR) | 0.14 | 1.37 |
| MACD | 0.05 | -0.23 |
| Stochastic Oscillator | 64.23 | 22.61 |
Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.